Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.
- NZ$36.1 million raised via placement and retail offer
- Retail offer oversubscribed with NZ$46 million in applications
- Over 93% of capital raised from existing shareholders
- New shares to commence trading on 4 June 2026
- Funds to support growth amid Medicare reimbursement progress
Oversubscribed Retail Offer Boosts Capital Raising
Pacific Edge (NZX/ASX:PEB) has wrapped up a NZ$36.1 million capital raising, exceeding initial targets thanks to a retail offer that attracted NZ$46 million in applications; nearly eight times the original NZ$6 million target. The company's board elected to accept NZ$4.7 million in oversubscriptions, bringing the retail offer total to NZ$10.7 million. Combined with a preceding NZ$25.4 million placement, this equity injection significantly strengthens Pacific Edge’s balance sheet.
Strong Support from Existing Shareholders
Notably, over 93% of the capital raised came from existing shareholders, highlighting confidence in Pacific Edge’s strategic direction. The retail offer was open exclusively to New Zealand-based shareholders on the register as of 8 May 2026, with allocations scaled to maintain relative shareholdings. This approach ensured most participants retained their stake or received their full application, a welcome outcome amid a robust demand environment.
Share Issuance and Trading Timeline
The 62.7 million new shares issued under the retail offer are priced at NZ$0.17 each and are expected to be allotted on 4 June 2026. These shares will rank equally with existing ordinary shares and will commence trading on the NZX the same day. Refunds for any surplus application amounts will be processed within five business days post-settlement.
Capital Raising Supports Cxbladder Commercial Momentum
Chairman Simon Flood emphasised that the capital raising positions Pacific Edge strongly for the future. He cited the growing clinical evidence underpinning Cxbladder, including support from the Novitas-convened Contractor Advisory Committee and expanding recognition from commercial payers. Early commercial wins in the Asia-Pacific region, combined with a draft Medicare Local Coverage Determination (LCD) in the US, underpin optimism about the product’s long-term opportunity.
Cxbladder, Pacific Edge’s genomic urine test suite for bladder cancer diagnosis and surveillance, is already accessible across multiple regions including the US, Australasia, Israel, Asia, and South America. In the US alone, over 5,000 urologists have ordered more than 130,000 tests, while in New Zealand, public healthcare covers approximately 70% of the population with additional access available online.
Clinical and Market Validation Underpin Growth Prospects
Supported by more than 20 years of research and over twenty-five peer-reviewed publications, Cxbladder has secured inclusion in the American Urological Association’s Microhematuria Guideline. The company continues to invest in clinical studies aimed at expanding evidence of utility and driving broader adoption, a critical factor as it seeks to convert Medicare draft coverage into final policy and commercial uptake in the US market.
Bottom Line?
Pacific Edge’s successful NZ$36.1 million raise, underpinned by strong shareholder backing and clinical validation, sets the stage for growth; but the market will be watching how Medicare coverage and commercial adoption unfold.
Questions in the middle?
- How will the final Medicare Local Coverage Determination impact Cxbladder’s US market penetration?
- What are the expected timelines for translating clinical evidence into commercial expansion across Asia-Pacific and South America?
- How will Pacific Edge deploy the new capital to balance growth initiatives against operational costs amid competitive diagnostic markets?